HOME2020-06-08T11:37:23+01:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

Check out our latest newsletter!

August 6th, 2020|

In the latest version of our newsletter, we hear from Richard Campbell about his experience as a person with Parkinson's joining our research meeting and interview two members of the research team. You can download the full newsletter here!

PD-MitoQUANT features in the current SYNAPSE eNewsletter

August 4th, 2020|

SYNAPSE is the Parkinson's UK quarterly newsletter for researchers. Typically, it publishes useful information about research funding, as well as events, news and opportunities in the world of research. The latest issue includes a small feature about the role of volunteers within the PD-MitoQUANT project and links to our March [...]

Parkinson’s UK hosts Research Conference 2020

July 6th, 2020|

Our partner Parkinson's UK is hosting an online research conference on September 24th and 25th, 2020. The 2020 theme is "Accelerating research and improving care". This is a CPD-accredited entirely online meeting held over two days. Keynote lectures will be delivered live from around the world. Symposia will be available [...]

Read more
Go to Top